Sales of monoclonal antibodies are projected to reach more than $160bn in the US alone over the next few years so is it any wonder that drug companies fiercely protect their profits? Allen Shaughnessy considers why these unique and complex drugs are so eyewateringly expensive
No takes yet. Share an insight, caveat, or question.
Allen F. Shaughnessy (2012) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: